Introduction {#s1}
============

Malaria caused by *Plasmodium falciparum* is a leading cause of mortality and morbidity globally, particularly among young children. After repeated exposure, individuals develop effective immunity that controls blood-stage parasitaemia, thereby reducing clinical symptoms and life-threatening complications (reviewed in [@pmed.1000218-Marsh1]). Antibodies are important mediators of acquired immunity to malaria as evidenced by experimental animal models and, most importantly, passive transfer studies in which antibodies from malaria-immune adults were successfully used to treat patients with severe malaria [@pmed.1000218-Cohen1],[@pmed.1000218-Sabchareon1]. Antibodies to merozoite antigens are considered important targets of protective antibodies and are thought to function in vivo by inhibiting merozoite invasion of erythrocytes, opsonizing merozoites for phagocytosis, and antibody-dependent cellular inhibition [@pmed.1000218-Cohen2]--[@pmed.1000218-BouharounTayoun1]. However, it is unclear which merozoite antigens are important targets of naturally acquired immunity.

A number of merozoite antigens have established roles in erythrocyte invasion and some have been identified as targets of human invasion-inhibition antibodies or antibody-dependent cellular inhibition in vitro [@pmed.1000218-Hodder1]--[@pmed.1000218-Persson1]. Merozoite surface proteins (MSPs) are thought to be involved in the initial attachment of the merozoite to the erythrocyte surface (e.g., MSP-1) and apical membrane antigen-1 (AMA-1) has been implicated in apical reorientation of the merozoite prior to invasion. Two invasion ligand families present in the apical organelles, the erythrocyte binding antigens (e.g., EBA175, EBA181, EBA140) and *P. falciparum* reticulocyte-binding homologues are also required for invasion [@pmed.1000218-Cowman1]. There are numerous surface proteins with no known function including MSP-2, MSP-3, MSP-4, and glutamate-rich protein (GLURP) [@pmed.1000218-Cowman1]. Genetic polymorphisms exist in most antigens and some can be grouped into major allelic types. Many of these antigens are currently being evaluated or developed as candidates for inclusion in an erythrocytic-stage malaria vaccine [@pmed.1000218-Richards1].

There are several criteria that can be used to objectively prioritize known and predicted antigens for vaccine development [@pmed.1000218-Richards1]. These include the demonstration that antibodies against these antigens inhibit *P. falciparum* growth in vitro, or are protective in animal models, and the demonstration that naturally acquired antibodies are associated with protection from symptomatic disease in malaria endemic populations. Consequently, numerous epidemiological studies have investigated the role of merozoite surface antigens as targets of human immunity. However, the epidemiological evidence of the protective effect of naturally acquired anti-merozoite responses is conflicting. There are numerous potential reasons for the inconsistencies in the estimates of protection. In malaria endemic areas the rate at which natural immunity develops is dependent on the intensity and stability of exposure to *P. falciparum*, with immunity to severe and mild disease developing more rapidly in areas with higher transmission [@pmed.1000218-Marsh1],[@pmed.1000218-Gupta1]. Differences in the acquisition of immunity may influence associations between specific responses and immunity. Furthermore, the prevalence of the major allelic types of specific antigens and subsequent acquisition of allele-specific immunity may be different across populations. The alleles represented in recombinant proteins used for determining antibody responses varies between studies in addition to the preparation of antigens used in immunoassays. Most importantly, the study designs used to investigate the associations between antibody responses and *P. falciparum* malaria studies vary considerably among the published literature. Evidence quoted in the literature regarding the protective role of antigen-specific antibodies is often based on data from cross-sectional or case-control studies. Examining the association of antibody responses with parasitological and clinical outcomes determined at a single time point, or in individuals who have already developed disease, makes the establishment of causality problematic. The highest level of evidence of causality in observational studies comes from prospective cohort studies in which a temporal relationship can be established between exposure and outcome.

We performed a systematic review, with meta-analyses, of cohort studies to determine the association of antibody responses to merozoite surface antigens with incidence of *P. falciparum* malaria in naturally exposed populations, and to identify factors that may account for differences in reported findings. The broad aim of this study was to advance our understanding of naturally acquired immunity to malaria and to contribute to rational vaccine development.

Materials and Methods {#s2}
=====================

We performed a systematic review of the published literature according to the Meta-analysis Of Observational Studies in Epidemiology (MOOSE) guidelines for the conduct of meta-analyses of observational studies [@pmed.1000218-Stroup1]. Results are reported according to the recently published PRISMA guidelines (Preferred Reporting Items for Systematic Reviews and Meta-Analyses; <http://www.prisma-statement.org>; [Text S1](#pmed.1000218.s001){ref-type="supplementary-material"}). The study protocol was developed by FJIF, JAS, and JGB.

Search Methods for Identification of Studies {#s2a}
--------------------------------------------

PubMed, Web of Science, Scopus, Google Scholar, African Index Medicus, and LILACS (Latin American and Caribbean Health Sciences Literature) (all years, ending 31 January 2009) were searched for studies examining the association of antibody responses to merozoite antigens with *P. falciparum* malaria. Key words included: MSP, merozoite surface protein, MSA, merozoite surface antigen, GLURP, glutamate-rich protein, serine repeat antigen, SERA, S-Antigen, ABRA, AMA, apical membrane antigen, EBA, erythrocyte binding antigen, rhoptry, malaria, *P. falciparum*, immunity, antibodies, IgG, cohort, longitudinal, incidence, risk, epidemiology, vaccine. The key words variant surface antigen (VSA) were also used because merozoite antigens are sometimes used as comparative antigens in studies investigating VSAs. The reference lists of obtained papers were searched for further studies. Studies reported in languages other than English were included.

Criteria for Considering Studies for This Review {#s2b}
------------------------------------------------

### Study designs {#s2b1}

The criteria for inclusion of studies were population-based prospective studies and population-based treatment to reinfection studies. Population-based cross-sectional studies to determine prevalence were excluded because causality cannot be established. Case-control studies, hospital-based studies, and vaccine efficacy trials of blood-stage vaccines were also excluded because of the rigorous inclusion and exclusion criteria applied during these studies, such that the participants would not be representative of the general population.

### Study participants {#s2b2}

The criterion for inclusion of participants was individuals living in malaria endemic areas. Studies restricted to pregnant women and/or children \<1 y (including maternal transfer studies) were excluded to remove the confounding effect of maternal transferred immunity. Studies where individuals were selected according to their *P. falciparum* status and studies investigating returned travellers or transmigrants were also excluded as they would not be representative of the general population.

### Antibody measures {#s2b3}

Total immunoglobulin G (IgG) responses to recombinant or synthetic defined merozoite antigens measured at baseline (i.e., time 0) were considered. IgG responses to full length proteins, processing products, and defined regions of merozoite antigens were included, but IgG responses to peptides that represent undefined regions or incomplete domains or subdomains of antigens were excluded.

### Malaria outcome measures {#s2b4}

The following malaria outcome measures during follow-up were included: high density *P. falciparum* infection (≥5,000/µl), symptomatic *P. falciparum* malaria, severe *P. falciparum* malaria, and *P. falciparum* malaria-associated mortality. In treatment-to-reinfection studies *P. falciparum* reinfection was also included as an outcome. Newly established blood-stage infection must have been differentiated from treatment failure by either PCR or documented clearance of infection within a specified time frame appropriate for the chosen antimalarial.

### Quality criteria {#s2b5}

The minimum quality criteria for inclusion in the review were that: detection of malaria was by active case detection (ACD) and/or passive case detection (PCD); parasitaemia was confirmed by slide microscopy, rapid detection kit, or PCR; symptomatic malaria was defined as fever and/or history of fever (within the past 72 h) plus a high density parasitaemia threshold (to increase specificity because low-grade parasitaemia is common in most settings); severe malaria was defined by the World Health Organization criteria and other causes of morbidity excluded; and other common causes of mortality excluded before a diagnosis of malaria-associated mortality [@pmed.1000218-World1],[@pmed.1000218-World2].

Selection of Studies {#s2c}
--------------------

Review authors (FJIF, JSR, and JGB) identified possible studies, FJIF and JSR assessed the methodological quality of included studies independently, with discrepancies resolved by discussion with JGB.

### Effort to include all available studies and data {#s2c1}

Authors of studies that had defined a case of symptomatic malaria as fever and/or history of fever plus a *P. falciparum* parasitaemia of any density (i.e., did not meet quality criteria of fever plus a high density threshold) were invited to provide estimates or data meeting the quality criteria. Some studies had analysed antibody levels at baseline as the outcome variable, comparing baseline levels in those who had or did not have *P. falciparum* malaria during follow-up. For these studies, data was extracted and reanalysed so that malaria was the outcome variable and related to antibodies at baseline. If the raw data were not presented, authors of the study were invited to reanalyse or provide data for the inclusion of their study in the systematic review. In addition, we contacted several authors whose studies did not meet the inclusion criteria yet contained data that were eligible for the systematic review. These were the authors of studies that had measured antibody responses after baseline (i.e., examined the association of antibody responses with malaria cases diagnosed both retrospectively and prospectively) and invited them to provide estimates or data concerning prospective *P. falciparum* incidence only. We also contacted authors who had restricted analysis to individuals who were parasite positive at baseline and invited them to provide estimates or data on the whole cohort where possible. If authors were unable to provide estimates or data, the study was classified as not meeting inclusion and/or quality criteria and excluded from the systematic review.

Data Analysis {#s2d}
-------------

### Data collection {#s2d1}

Measures of association (odds ratios \[ORs\], risk ratios \[RRs\], incidence rate ratios \[IRRs\], or hazard ratios \[HRs\]) and their 95% confidence intervals (CIs) were extracted or derived using data reported in the publications. Data extraction was performed independently by FJIF and JSR, using proforma designed by FJIF, JAS, and JGB. The investigators of the original studies were contacted if relevant information on eligibility or key study data were not available in the published report. An email was sent to authors explaining the nature of the systematic review and the information required together with proforma. If the author did not respond within three email attempts then no further action was taken. Where a study does not provide measures of association (or they could not be calculated with the information provided), the study results will be described only in narrative terms.

### Standardization of antibody measures {#s2d2}

A major issue in reviewing the published results of different epidemiologic studies examining the relation between an exposure variable and risk of the outcome is that the results are presented in many different ways. Determining antibody levels by enzyme-linked immunosorbent assay (ELISA) does not produce a common metric measurement among studies. Individuals can be classified as "responders" or "nonresponders" relative to a negative control (unexposed sera) within each study. Study-specific comparisons of these exposure variables can then be pooled. However, categories based on arbitrary cut-offs (including categories of responders based on statistical rankings) cannot be pooled across studies.

For studies where the antibody measures were analysed as continuous exposure variables we either asked the authors to reanalyse their data by collapsing the antibody data into categories or asked them to provide the standard deviation of the data so we could calibrate the estimate to represent the relative change in the risk of malaria associated with a change of one standard deviation of the antibody level. For log transformed antibody data we used log base 2 so that the relative change in malaria risk corresponds to a doubling of antibody level.

### Standardization of malaria outcome measures {#s2d3}

ORs considerably overestimate the RR, if the incidence risk is \>20%, which is often the case in highly malaria endemic areas [@pmed.1000218-Egger1]. Thus, RR, HR, and IRR were extracted or calculated where possible, or unadjusted ORs were converted to RR using the method of Zhang and Yu [@pmed.1000218-Zhang1]. RR, HR, and IRR are hereinafter denoted as RR. A RR equal to 1 occurs when the incidence risk of malaria is equal for those with antibody responses (responders) and those without (nonresponders), and when the incidence risk is unchanged for 2-fold increases in the antibody levels. Where possible, estimates adjusted for demographic variables, spatial confounders, *P. falciparum* parasitaemia (at baseline or preseason), and/or bed net use are reported. Estimates adjusted for other anti-merozoite antibodies (including antibodies to schizont protein extract) are not reported because antibody responses are typically highly correlated making it difficult to estimate their individual regression coefficients reliably; in these cases unadjusted estimates are reported. For all malaria outcomes the study-assigned *P. falciparum* definitions were used.

Our aim was to obtain a single RR estimate for each study. If antibody responses to the same antigen, in the same population-based study, were reported in several publications, results from the largest sample size were used. Separate estimates were obtained for the RR associated with AMA-1 (full-length ectodomains of FVO \[pro-DI-DII-DIII\] and 3D7 \[DI-DII-DIII\]), EBA-175 (all regions including F1 and F2), GLURP (R0, R1, and R2 fragments), MSP-2 (full length 3D7, full length FC27, and C terminus), MSP-3 (full length 3D7, full length K1, and the conserved C terminus). For MSP-1, separate analyses were done for each region and allelic type (MSP-1-block 1 \[MAD20\], MSP-1-block 2 \[K1-like (3D7), MAD20-like \[MAD20\], and RO33-like \[RO33\]), and processing fragments (MSP-1~42~, MSP-1~19~ \[including MSP-1-EGF1, MSP-1-EGF2\]). Estimates from the above-mentioned regions/alleles were used to ensure maximum comparability between studies. Separate analyses were not done for MSP-3-Ct or MSP-1~19~ alleles because of the conserved nature of MSP-3-Ct and MSP-1~19~ (similarly EGF domains). For these antigens, if responses to multiple alleles were investigated in the same study, the most common circulating allele in the population was included in the meta-analysis.

### Meta-analysis {#s2d4}

Where there were sufficient data, a pooled summary statistic for each malaria outcome was calculated using either a fixed-effect or random-effects model. The standard error of the natural logarithm (ln) of the RR was calculated using the formula (ln\[upper limit of CI\]−ln\[RR\])/1.96. Heterogeneity between studies was tested with the *I* ^2^ statistic [@pmed.1000218-Higgins1]. If the *I* ^2^ statistic was ≤30%, a meta-analysis based on a fixed-effect model was conducted; otherwise the random-effects model was used. When the *I* ^2^ statistic was \>75% and/or the lower 95% confidence limit was between 50%--100%, the studies were not combined [@pmed.1000218-Ioannidis1]. When statistical heterogeneity was noted it was evaluated by fitting meta-regression models to the log-transformed individual study RRs.

Clinical and methodological heterogeneity was explored using prespecified variables to minimize spurious findings. Variables evaluated included study design (prospective cohort, treatment-to-reinfection), length of follow-up, age of study participants (dichotomous variable: adults and children, children only), malaria endemicity (perennial, seasonal, perennial with seasonal peaks), source of malaria cases (dichotomous variable: ACD only, PCD, and ACD), definition of symptomatic malaria, preparation of antigen (allele, expression vector, tag), and method of antibody determination (ELISA, microarray). Influence analysis was also performed whereby pooled estimates were calculated omitting one study at a time. Where possible, publication bias was assessed visually by plotting a funnel plot [@pmed.1000218-Sterne1]; publication bias is unlikely if the funnel plots shows a symmetrical inverted V shape [@pmed.1000218-Egger2]. All analyses were performed using the open source statistical package, R 2.9.0 (R Foundation for Statistical Computing).

Results {#s3}
=======

Identification and Description of Included Studies {#s3a}
--------------------------------------------------

[Figure 1](#pmed-1000218-g001){ref-type="fig"} outlines identification of studies for this systematic review. The literature search identified 73 potentially relevant studies, of which only 30 fulfilled the inclusion and quality criteria (details of excluded studies can be found in [Text S2](#pmed.1000218.s002){ref-type="supplementary-material"}) [@pmed.1000218-Meraldi1]--[@pmed.1000218-Wang1]. We obtained further data from three studies after contacting authors ([Figure 1](#pmed-1000218-g001){ref-type="fig"}), giving a total of 33 studies to be included in the systematic review [@pmed.1000218-Scopel1]--[@pmed.1000218-Sarr1].

![Flow chart of study identification.\
Details of excluded studies can be found in [Text S2](#pmed.1000218.s002){ref-type="supplementary-material"}. ^a^Definition of symptomatic malaria did not meet protocol definition; ^b^Analysed retro- and prospectively collected clinical data (*n* = 3), analysed antibody levels as outcome (*n* = 4,) and data presented on *P. falciparum* positive individuals only (*n* = 1); ^c^Reasons for exclusion: Data from seroprevalence surveys (*n* = 15); hospital-based study/recruited cases based on clinical/parasitemic status (*n* = 6); did not include malaria outcome of interest (*n* = 5); mother/infant studies (*n* = 3); measured IgG responses to undefined regions of antigens (*n* = 1); ^d^Scopel et al. (2007) provided data using a definition of symptomatic malaria that met our quality criteria, Sarr et al. (2006) provided data so *P. falciparum* could be analysed as outcome, and Osier et al. (2008) provided estimates for the whole cohort, whereas the manuscript originally presented data from *P. falciparum*-positive individuals only [@pmed.1000218-Scopel1]--; ^e^The characteristics of included studies are given in [Table 1](#pmed-1000218-t001){ref-type="table"}.](pmed.1000218.g001){#pmed-1000218-g001}

The 33 studies reported data obtained from 14 separate prospective cohort studies and six separate treatment-to-reinfection population studies ([Tables 1](#pmed-1000218-t001){ref-type="table"} and [2](#pmed-1000218-t002){ref-type="table"}, respectively) indicating that multiple publications arise from a single population-based study. For the purpose of this review we shall refer to each publication as a study. The majority of studies report data from Africa (28/33; 84.8%), with three in Papua New Guinea, one in Asia, and one from South America. Study size ranged from 80 to 1,071 participants (median = 280) and duration of participant follow-up ranged from 3 to 18 mo (median = 6). The association of antibody responses to MSP-1 (including processing fragments and defined blocks), MSP-2, and MSP-3, AMA-1, EBA-175, and GLURP with incidence risk of *P. falciparum* malaria was examined in 19, eight, seven, five, three, and six studies, respectively. Details of recombinant proteins and sero-prevalences can be found in [Text S2](#pmed.1000218.s002){ref-type="supplementary-material"} (Tables A and B). All studies measured total IgG by ELISA with the exception of Gray et al. (2007), who measured IgG by microarray [@pmed.1000218-Gray1]. Symptomatic *P. falciparum* malaria during follow-up was the most common outcome, examined in 29 studies; with reinfection and high density infection during follow-up examined in five and three studies, respectively. No study examined the association of anti-merozoite responses with incidence risk of severe *P. falciparum* malaria or *P. falciparum* malaria-associated mortality.

10.1371/journal.pmed.1000218.t001

###### Characteristics of prospective studies included in the systematic review by country.

![](pmed.1000218.t001){#pmed-1000218-t001-1}

  Country                                     Study: Author, Year \[Reference\]                         Province      Follow-up (mo)   Population   Merozoite IgG Response                                            *P. falciparum* Outcome                                                      
  ---------------------- --------------------------------------------------------------------------- --------------- ---------------- ------------ ------------------------ ----------------------------------------------------------------------------------------------------------- ---------- ------------------------------------------------------------
  **Brazil**                                Scopel, 2007 [@pmed.1000218-Scopel1]                          Acre              15            356               5--65                                                              MSP-2                                                     ACD, PCD    Symptomatic *Pf* [c](#nt105){ref-type="table-fn"} (6.5)
  **Burkina Faso**                         Meraldi, 2004 [@pmed.1000218-Meraldi1]                        Kadiogo            7             293               0.5--9                                                         GLURP, MSP-3                                                    ACD        Symptomatic *Pf* [d](#nt106){ref-type="table-fn"} (49)
                                             Nebie, 2008 [@pmed.1000218-Nebie1]                          Bazega             4             286              0.5--15                                                AMA-1, GLURP, MSP-1~19~, MSP-3                                           ACD        Symptomatic *Pf* [d](#nt106){ref-type="table-fn"} (41)
                                             Nebie, 2008 [@pmed.1000218-Nebie2]                          Bazega             4             360              0.5--10                                                         GLURP, MSP-3                                                    ACD       Symptomatic *Pf* [d](#nt106){ref-type="table-fn"} (DNS)
  **The Gambia**            Conway, 2000 [@pmed.1000218-Conway1] [a](#nt102){ref-type="table-fn"}      Upper River          5             337                3--7                                                 MSP-1~19~, MSP-1-BL1, MSP-1-BL2                                        ACD, PCD     Symptomatic *Pf* [d](#nt106){ref-type="table-fn"} (19)
                            Polley, 2003 [@pmed.1000218-Polley1] [a](#nt102){ref-type="table-fn"}      Upper River          5             334                3--7                                                            MSP-1-BL2                                                   ACD, PCD     Symptomatic *Pf* [d](#nt106){ref-type="table-fn"} (19)
                           Metzger, 2003 [@pmed.1000218-Metzger1] [a](#nt102){ref-type="table-fn"}     Upper River          5             329                3--7                                                              MSP-2                                                     ACD, PCD     Symptomatic *Pf* [d](#nt106){ref-type="table-fn"} (19)
                            Polley, 2007 [@pmed.1000218-Polley2] [a](#nt102){ref-type="table-fn"}      Upper River          5             319                3--7                                                              MSP-3                                                     ACD, PCD     Symptomatic *Pf* [d](#nt106){ref-type="table-fn"} (19)
                          Dziegiel, 1993 [@pmed.1000218-Dziegiel1] [a](#nt102){ref-type="table-fn"}    North Bank           6             385                3--8                                                              GLURP                                                       ACD        Symptomatic *Pf* [d](#nt106){ref-type="table-fn"} (35)
                              Egan, 1996 [@pmed.1000218-Egan1] [a](#nt102){ref-type="table-fn"}        North Bank           6             327                3--8                                                      MSP-1~19~, MSP-1-EGF                                                ACD        Symptomatic *Pf* [d](#nt106){ref-type="table-fn"} (35)
                            Taylor, 1998 [@pmed.1000218-Taylor1] [a](#nt102){ref-type="table-fn"}      North Bank           6             355                3--8                                                              MSP-2                                                       ACD        Symptomatic *Pf* [d](#nt106){ref-type="table-fn"} (35)
                             Okenu, 2000 [@pmed.1000218-Okenu1] [a](#nt102){ref-type="table-fn"}       North Bank           6             284                3--8                                                             EBA-175                                                      ACD        Symptomatic *Pf* [d](#nt106){ref-type="table-fn"} (35)
                             Okech, 2004 [@pmed.1000218-Okech1] [a](#nt102){ref-type="table-fn"}       North Bank           6             260                3--8                                           MSP-1~19~ [b](#nt103){ref-type="table-fn"}                                     ACD        Symptomatic *Pf* [d](#nt106){ref-type="table-fn"} (35)
                              Gray, 2007 [@pmed.1000218-Gray1] [a](#nt102){ref-type="table-fn"}        North Bank           6             189                3--8            AMA-1, MSP-1~19~,[b](#nt103){ref-type="table-fn"} MSP-1-BL2, MSP-2,[b](#nt103){ref-type="table-fn"} MSP-3     ACD        Symptomatic *Pf* [d](#nt106){ref-type="table-fn"} (35)
  **Ghana**                  Dodoo, 1999 [@pmed.1000218-Dodoo1] [a](#nt102){ref-type="table-fn"}      Greater Accra         18            266               3--15                                      MSP-1~19~,[b](#nt103){ref-type="table-fn"} MSP-1-EGF                              ACD, PCD     Symptomatic *Pf* [e](#nt107){ref-type="table-fn"} (41)
                             Dodoo, 2000 [@pmed.1000218-Dodoo2] [a](#nt102){ref-type="table-fn"}      Greater Accra         18            115               3--15                                                              GLURP                                                     ACD, PCD     Symptomatic *Pf* [e](#nt107){ref-type="table-fn"} (41)
                          Cavanagh, 2004 [@pmed.1000218-Cavanagh1] [a](#nt102){ref-type="table-fn"}   Greater Accra         18            280               3--15                                                 MSP-1~19~, MSP-1-BL1, MSP-1-BL2                                        ACD, PCD     Symptomatic *Pf* [e](#nt107){ref-type="table-fn"} (41)
                                             Dodoo, 2008 [@pmed.1000218-Dodoo3]                       Greater Accra         9             352               3--10                                                 AMA-1, GLURP, MSP-1~19~, MSP-3                                         ACD, PCD     Symptomatic *Pf* [e](#nt107){ref-type="table-fn"} (19)
  **Kenya**                 Polley, 2004 [@pmed.1000218-Polley3] [a](#nt102){ref-type="table-fn"}         Coast             6            1,071             0.1--85                                                             AMA-1                                                     ACD, PCD   Symptomatic *Pf* [f](#nt108){ref-type="table-fn"} (15, 26)
                            Polley, 2006 [@pmed.1000218-Polley4] [a](#nt102){ref-type="table-fn"}         Coast             6            1,068             0.1--85                                                             MSP-2                                                     ACD, PCD   Symptomatic *Pf* [f](#nt108){ref-type="table-fn"} (15, 26)
                             Osier, 2007 [@pmed.1000218-Osier1] [a](#nt102){ref-type="table-fn"}          Coast             6             536              0.1--85                                                             MSP-3                                                     ACD, PCD     Symptomatic *Pf* [f](#nt108){ref-type="table-fn"} (15)
                             Osier, 2008 [@pmed.1000218-Osier2] [a](#nt102){ref-type="table-fn"}          Coast             6             280              0.1--85                                                 EBA-175, MSP-1~19~, MSP-1-BL2                                         ACD, PCD     Symptomatic *Pf* [f](#nt108){ref-type="table-fn"} (24)
  **Papua New Guinea**    Al-Yaman, 1995 [@pmed.1000218-AlYaman1] [a](#nt102){ref-type="table-fn"}     East Sepik           12            230              0.5--15                                                             MSP-2                                                     ACD, PCD    Symptomatic *Pf* [e](#nt107){ref-type="table-fn"} (DNS)
                          Al-Yaman, 1996 [@pmed.1000218-AlYaman2] [a](#nt102){ref-type="table-fn"}     East Sepik           12            230              0.5--15                                                           MSP-1~42~                                                   ACD, PCD    Symptomatic *Pf* [e](#nt107){ref-type="table-fn"} (DNS)
  **Senegal**                              Perraut, 2005 [@pmed.1000218-Perraut1]                        Fatick             5             205               3--75                                                            MSP-1~19~                                                   ACD, PCD     Symptomatic *Pf* [g](#nt109){ref-type="table-fn"} (60)
                                              Sarr, 2006 [@pmed.1000218-Sarr1]                           Fatick             6             169               2--10                                                              MSP-2                                                       ACD        Symptomatic *Pf* [h](#nt110){ref-type="table-fn"} (53)
  **Sierra-Leone**                            Egan, 1996 [@pmed.1000218-Egan1]                          Southern            12            645                0--8                                                      MSP-1~19~, MSP-1-EGF                                                ACD        Symptomatic *Pf* [d](#nt106){ref-type="table-fn"} (42)
  **Tanzania**                             Lusingu, 2005 [@pmed.1000218-Lusingu1]                         Tanga             6             171               0--19                                                              GLURP                                                     ACD, PCD     Symptomatic *Pf* [e](#nt107){ref-type="table-fn"} (32)

Sample size refers to number of participants whose serology was determined. IgG responses measured by ELISA with the exception of Gray et al. [@pmed.1000218-Gray1] who used microarray immunoassays. Manuscripts by Egan et al. [@pmed.1000218-Egan1] and Okech et al. [@pmed.1000218-Okech1] report studies performed in two countries and feature twice in [Table 1](#pmed-1000218-t001){ref-type="table"} and once in [Tables 1](#pmed-1000218-t001){ref-type="table"} and [2](#pmed-1000218-t002){ref-type="table"}, respectively. Studies by Polley et al. [@pmed.1000218-Polley3],[@pmed.1000218-Polley4] in the Kenyan coast were done at two study sites.

Indicates that the different antibody association studies were performed in the same cohort for the specified country and province. In The Gambia, the "Upper River" and "North Bank" studies were separate cohorts.

Antigen was not included in meta-analysis (as per protocol).

Malaria definitions:

History of fever plus *P. falciparum* \>300/µl.

Fever plus *P. falciparum* ≥5,000/µl or fever plus *P. falciparum* \>5,000/µl.

Fever or history of fever (within the past 72 h) plus *P. falciparum* ≥5,000/µl.

Fever plus an age-dependent threshold of *P. falciparum*.

Fever plus \>30 *P. falciparum* trophozoites/100 leukocytes.

Fever plus *P. falciparum* \>2,500/µl.

*Pf*, *P. falciparum*.

10.1371/journal.pmed.1000218.t002

###### Characteristics of prospective treatment-to-reinfection studies included in the systematic review by country.

![](pmed.1000218.t002){#pmed-1000218-t002-2}

  Country                                 Study: Author, Year \[Reference\]                      Province       Antimalarial   Follow-up (mo)   Population   Merozoite IgG Response                     *P. falciparum* Outcome                                
  ---------------------- ------------------------------------------------------------------- ----------------- -------------- ---------------- ------------ ------------------------ -------------------------------------------------------------- ---------- ------------------------------------------------------------------------------------------------------------------------------------------
  **Kenya**               John, 2004 [@pmed.1000218-John1] [a](#nt113){ref-type="table-fn"}     Rift Valley          SP              3              84               1--80                                     MSP-1~19~                             ACD, PCD                                                               Reinfection (45)
                          John, 2005 [@pmed.1000218-John2] [a](#nt113){ref-type="table-fn"}     Rift Valley          SP              3              84               1--80            AMA-1, EBA-175, *MSP-1~19~* [b](#nt114){ref-type="table-fn"}   ACD, PCD                                                               Reinfection (45)
  **Mali**                               Tolle, 1993 [@pmed.1000218-Tolle1]                       Bamako             CQ              7             191             1 to \>15                                   MSP-1-BL2                               ACD                                            High *Pf* density \[[c](#nt116){ref-type="table-fn"}\] (DNS)
  **Papua New Guinea**                Stanisic, 2009 [@pmed.1000218-Stanisic1]                    Madang             A               6             206               5--14                              AMA-1, MSP-1~19~, MSP-2                      ACD, PCD   Reinfection (95), High *Pf* density \[[c](#nt116){ref-type="table-fn"}\] (52), Symptomatic *Pf*\[[d](#nt117){ref-type="table-fn"}\] (49)
  **Senegal**                          Perraut, 2003 [@pmed.1000218-Perraut2]                     Fatick             Q               5             110               2--73                                     MSP-1~19~                               ACD                                    Reinfection (93), Symptomatic *Pf*\[[e](#nt118){ref-type="table-fn"}\] (66)
  **Uganda**                             Okech, 2004 [@pmed.1000218-Okech1]                   Northern Region        SP              5             156               7--16                                     MSP-1~19~                               ACD                                            High *Pf* density \[[c](#nt116){ref-type="table-fn"}\] (18)
  **Vietnam**                             Wang, 2001 [@pmed.1000218-Wang1]                       Khanh-Hoa        Q+D+*P*            6             112               9--55                                  MSP-1~19~, MSP-4                           ACD                                                                  Reinfection (42)

Sample size refers to number of participants whose serology was determined. IgG responses measured by ELISA. Okech (2004) [@pmed.1000218-Okech1] performed studies in two countries and also features in [Table 1](#pmed-1000218-t001){ref-type="table"}.

Indicates that the different antibody association studies were performed in the same cohort for the specified country and province.

Antigen was not included in meta-analysis (as per protocol).

Malaria definitions:

*P. falciparum* \>5,000/µl.

Fever plus *P. falciparum* ≥5,000/µl or fever plus *P. falciparum* \>5,000/µl.

Fever plus \>30 *P. falciparum* trophozoites/100 leukocytes.

A, artesunate; CQ, chloroquine; D, Doxycyline; MSP-1-BL2r, Block 2 repeats; *P*, Primaquine; *Pf*, *P. falciparum*; Q, quinine; SP, sulfadoxine-pyrimethamine.

Association between Anti-MSP-1 Responses and Incidence of *P. falciparum* Malaria {#s3b}
---------------------------------------------------------------------------------

### MSP-1 C-terminal (Ct)--processing fragments {#s3b1}

MSP-1 is a high molecular mass protein (Mr≈180 kDa) that is proteolytically processed into 83 kDa, 30 kDa, 38 kDa, and C-terminal 42 kDa (MSP-1~42~) fragments [@pmed.1000218-Koussis1]. During invasion, MSP-1~42~ is further processed into MSP-1~19~ and MSP-1~33~ fragments. Both MSP-1~19~ and MSP-1~42~ are regarded as potential vaccine candidates and have been shown to be protective in animal models [@pmed.1000218-Richards1]. Meta-analysis of five studies showed that MSP-1~19~ IgG responders had an 18% reduction in the risk of symptomatic *P. falciparum* malaria compared to nonresponders (pooled RR using random-effects \[reRR\] 0.82, 95% CI 0.7--0.96, *p* = 0.012; [Figure 2](#pmed-1000218-g002){ref-type="fig"}) [@pmed.1000218-Conway1],[@pmed.1000218-Egan1] [@pmed.1000218-Cavanagh1] [@pmed.1000218-Perraut1] [@pmed.1000218-Osier2]. Meta-regression analysis revealed heterogeneity between allelic groups (*p* = 0.0223) with the greatest magnitude of effect seen with MAD20 and Palo Alto alleles (29% and 33% relative reduction in symptomatic disease, respectively; [Figure 2](#pmed-1000218-g002){ref-type="fig"}). Because the methods for the preparation of each antigen was the same for each allelic variant ([Text S2](#pmed.1000218.s002){ref-type="supplementary-material"}, Table A) similar results were obtained when grouping according to expression system and tag used to make the recombinant antigen. Other methodological and clinical characteristics of the studies did not influence estimates and there was no evidence of publication bias.

![Forest plot of the association of MSP-1~19~ responses with incidence of symptomatic *P. falciparum* malaria.\
RRs correspond to risk of symptomatic *P. falciparum* malaria for MSP-1~19~ responders versus nonresponders and per doubling of antibody responses (log base 2). RR\<1 indicate that antibody responses are protective against symptomatic *P. falciparum* whereas RR\>1 indicate susceptibility. ^a^Estimates are calculated by authors from data in the paper; ^b^data supplied by original authors and calculated by current authors; ^c^estimates are published estimates. All estimates are unadjusted with the exception of estimates from Nebie et al. (2008) and Dodoo et al. (2008), which are adjusted for age, and estimates from Stanisic (2009) are adjusted for age and spatial confounders [@pmed.1000218-Nebie1],[@pmed.1000218-Dodoo3],[@pmed.1000218-Stanisic1]. W, weight. Note: Egan, 1996 had two study sites \*Sierra-Leone and \*\*The Gambia, and their analysis only included those with clinical disease versus asymptomatics, i.e., excluded those uninfected as they were assumed to be unexposed [@pmed.1000218-Egan1].](pmed.1000218.g002){#pmed-1000218-g002}

Data were obtained from a further three studies and pooled to examine the dose-response association of MSP-1~19~ levels (log base 2) and the risk of malaria [@pmed.1000218-Nebie1],[@pmed.1000218-Dodoo3],[@pmed.1000218-Stanisic1]. A 15% reduction in symptomatic *P. falciparum* per doubling of antibody levels was observed (reRR 0.85, 95% CI 0.74--0.97, *p* = 0.019; [Figure 2](#pmed-1000218-g002){ref-type="fig"}). With only three studies in the meta-analysis, further subgroup analysis was not feasible. One additional study examined the association of antibody levels (excluded from meta-analysis because transformation, if any, was not stated in the original manuscript) with symptomatic *P. falciparum* and found weak evidence of a protective effect (RR 0.97, 95% CI 0.94--1.00, *p* = 0.0713) [@pmed.1000218-Perraut2]. There was no conclusive evidence to support an association between anti-MSP-1~19~ responses with *P. falciparum* high density infection or reinfection (see [Text S2](#pmed.1000218.s002){ref-type="supplementary-material"}).

MSP-1~19~ is made up of two epidermal growth factor-like modules (EGF-1 and EGF-2). Meta-analyses showed no association between the presence of responses to either MSP-1-EGF1 or MSP-1-EGF2 with protection against symptomatic *P. falciparum* (RR 1.06, 95% CI 0.88--1.26, *p* = 0.56 and reRR 0.59, 95% CI 0.19--1.84, *p* = 0.37; *I* ^2^ = 71.4%, 95% CI 2.8--91.6%, respectively) [@pmed.1000218-Egan1],[@pmed.1000218-Dodoo1]. For individual study estimates see [Text S2](#pmed.1000218.s002){ref-type="supplementary-material"}.

Only one study examined the association of MSP-1~42~ levels (log base 2) with incidence risk of symptomatic *P. falciparum* and found a reduced risk (RR 0.76, 95% CI data not shown in original manuscript \[DNS\], *p*≤0.001) [@pmed.1000218-AlYaman2].

### MSP-1 polymorphic N-terminal regions {#s3b2}

MSP-1 block 2 can be grouped into three allelic types, K1-like, RO33-like, and MAD20 like. The association of incidence risk of symptomatic *P. falciparum* with allelic specific MSP-1 block 2 responders compared to nonresponders was examined in four studies [@pmed.1000218-Conway1],[@pmed.1000218-Gray1],[@pmed.1000218-Cavanagh1],[@pmed.1000218-Osier2]. Pooled results were done separately for each allelic type. Meta-analysis revealed no evidence of an association with the K1-like (reRR 0.88, 95% CI 0.67, 1.17, *p* = 0.39) or RO33-like allele (RR 0.99, 95% CI 0.81, 1.21, *p* = 0.91) ([Figure 3](#pmed-1000218-g003){ref-type="fig"}). There was weak evidence of a protective effect of MAD20-like responses with incidence risk of symptomatic *P. falciparum* (reRR 0.79, 95% CI 0.6, 1.04, *p* = 0.093; [Figure 3](#pmed-1000218-g003){ref-type="fig"}).

![Forest plot of the association of MSP-1 block 2 and block 1 responses with incidence of symptomatic *P. falciparum* malaria.\
RRs represent the risk of symptomatic *P. falciparum* malaria in IgG responders relative to nonresponders. RR\<1 indicate that responders are protected from symptomatic *P. falciparum* whereas RR\>1 indicate susceptibility. ^a^Estimates are published estimates; ^b^estimates are calculated by authors from data in the paper; ^c^data supplied by original authors and calculated by current authors. All reported estimates are unadjusted. W, weight.](pmed.1000218.g003){#pmed-1000218-g003}

The K1-like and MAD20-like types of MSP-1 block 2 differ in the length of tri-peptide repeats in the middle of the block as well as the flanking nonrepetitive sequences. Meta-analysis was performed on three studies investigating the association between responses to MSP-1 block 2 repeats and flanking regions (responders versus nonresponders) and incidence risk of symptomatic *P. falciparum* [@pmed.1000218-Polley1],[@pmed.1000218-Gray1],[@pmed.1000218-Cavanagh1]. There was some evidence of an association for MSP-1 block 2 K1-like repeats (RR 0.72, 95% CI 0.54--0.97, *p* = 0.031) but not MSP-1 block 2 MAD20-like repeats (reRR 0.79, 95% CI 0.48--1.3, *p* = 0.35) ([Figure 4](#pmed-1000218-g004){ref-type="fig"}). There was also no evidence of an association between MSP-1 block 2 flanking regions with risk of symptomatic *P. falciparum* (K1-like RR 0.87, 95% CI 0.66--1.14, *p* = 0.31 and MAD20-like reRR 0.84, 95% CI 0.52--1.34, *p* = 0.46; [Figure 4](#pmed-1000218-g004){ref-type="fig"}).

![Forest plot of the association of MSP-1-block 2 repeats and flanking region responses with incidence of symptomatic *P. falciparum* malaria.\
RRs represent the risk of symptomatic *P. falciparum* malaria in IgG responders relative to nonresponders. RR\<1 indicate that responders are protected from symptomatic *P. falciparum* whereas RR\>1 indicate susceptibility. ^a^Estimates are published estimates; ^b^estimates are calculated by authors from data in the paper. All reported estimates are unadjusted. W, weight.](pmed.1000218.g004){#pmed-1000218-g004}

Combined results from two studies showed no evidence of an association of MSP-1 block 1 responses with risk of symptomatic falciparum malaria (responders versus nonresponders RR 0.96, 95% CI 0.57--1.62, *p* = 0.88; [Figure 4](#pmed-1000218-g004){ref-type="fig"}) [@pmed.1000218-Conway1],[@pmed.1000218-Cavanagh1].

Association between Anti-MSP-2 Responses and Incidence of *P. falciparum* Malaria {#s3c}
---------------------------------------------------------------------------------

The single *msp2* locus of *P. falciparum* is highly polymorphic but can be grouped into two major allelic types, 3D7 and FC27. Meta-analysis of six studies investigating MSP-2~3D7~ and MSP-2~FC27~ showed no evidence of a reduced risk of symptomatic *P. falciparum* in those with responses compared to those without responses (MSP-2~3D7~, reRR 0.92, 95% CI 0.75--1.13, *p* = 0.43; MSP-2~FC27~, reRR 0.82, 95% CI 0.62--1.08, *p* = 0.16, [Figure 5](#pmed-1000218-g005){ref-type="fig"}) [@pmed.1000218-Metzger1],[@pmed.1000218-Taylor1],[@pmed.1000218-Polley4],[@pmed.1000218-Stanisic1],[@pmed.1000218-Scopel1],[@pmed.1000218-Sarr1]. Methodological and clinical characteristics of the studies did not influence estimates and there was no evidence of publication bias. One additional study found a dose-dependent response with MSP-2~3D7~ antibody levels (log base 2) and risk of symptomatic *P. falciparum* (RR 0.81, 95% CI DNS, *p* = 0.003) but not MSP-2~FC27~ (RR 0.99, 95% CI DNS, *p* = 0.86) [@pmed.1000218-AlYaman1]. Another study examined the effect of MSP-2-Ct (responders versus nonresponders) and found no evidence of an association with symptomatic *P. falciparum* (RR 0.55, 95% CI 0.27, 1.14, *p* = 0.11) [@pmed.1000218-Metzger1]. Only one study examined the association of MSP-2 antibodies with reinfection and high density infection and found no association (see [Text S2](#pmed.1000218.s002){ref-type="supplementary-material"}) [@pmed.1000218-Stanisic1].

![Forest plot of the association of MSP-2 responses with incidence of symptomatic *P. falciparum* malaria.\
RR\<1 indicate that responders are protected from symptomatic *P. falciparum* compared to nonresponders whereas RR\>1 indicate susceptibility. ^a^Estimates are published estimates; ^b^converted published estimate; ^c^estimates are calculated by authors from data supplied by original author; ^d^estimates are calculated by authors from data in the paper. W, weight. Estimates reported are unadjusted with the exception of Stanisic (2009) (adjusted for spatial confounders and age) and Metzger (2003) (adjusted for age and preseason parasitaemia) [@pmed.1000218-Metzger1],[@pmed.1000218-Stanisic1]. Note that estimates for Taylor (1998) are based on clinical and asymptomatic cases only (i.e., those uninfected were excluded on the basis they were unexposed) [@pmed.1000218-Taylor1]. Polley (2006) stratified for two study sites in Coastal Kenya, \*Chonyi and \*\*Ngerenya [@pmed.1000218-Polley4].](pmed.1000218.g005){#pmed-1000218-g005}

Association between Anti-MSP-3 Responses and Incidence of *P. falciparum* Malaria {#s3d}
---------------------------------------------------------------------------------

The C-terminal region of MSP-3 (MSP-3-Ct) is highly conserved whereas the remainder of the sequence is defined by two major allelic types, 3D7 and K1 [@pmed.1000218-Huber1]. Meta-analyses of four studies [@pmed.1000218-Meraldi1],[@pmed.1000218-Nebie2],[@pmed.1000218-Polley2],[@pmed.1000218-Osier1] examining antibodies to MSP-3-Ct responses showed a 54% reduction in symptomatic *P. falciparum* in responders versus nonresponders (RR 0.46, 95% CI 0.32--0.67, *p*\<0.0001; [Figure 6](#pmed-1000218-g006){ref-type="fig"}). Meta-analyses of two studies also showed a decreased incidence risk per doubling of MSP-3-Ct antibody levels (RR 0.73, 95% CI 0.6--0.88, *p* = 0.001, [Figure 6](#pmed-1000218-g006){ref-type="fig"}) [@pmed.1000218-Nebie1],[@pmed.1000218-Dodoo3].

![Forest plot of the association of MSP-3 responses with incidence of symptomatic *P. falciparum* malaria.\
RR\<1 indicate protection from symptomatic *P. falciparum* whereas RR\>1 indicate susceptibility in responders versus nonresponders or per doubling of antibody responses. Estimates reported are unadjusted with the exception of Nebie (2008) (adjusted for age, sex, and village) [@pmed.1000218-Nebie2] and Nebie (2008) and Dodoo (2008) (adjusted for age) [@pmed.1000218-Nebie1],[@pmed.1000218-Dodoo3]. ^a^Estimates are calculated by authors from data in the paper; ^b^estimates are published estimates. All reported estimates are unadjusted. W, weight.](pmed.1000218.g006){#pmed-1000218-g006}

Three studies examined the association of full length MSP-3~3D7~ and MSP-3~K1~ responses (responders versus nonresponders) with risk of symptomatic *P. falciparum* [@pmed.1000218-Polley2],[@pmed.1000218-Gray1],[@pmed.1000218-Osier1]. Meta-analysis showed no evidence of an association with anti-MSP-3~3D7~ responses (reRR 0.92, 95% CI 0.64--1.31, *p* = 0.63; [Figure 6](#pmed-1000218-g006){ref-type="fig"}), but a large amount of heterogeneity was observed (*I* ^2^ = 67.6%, 95% CI 0--90.6%). A high degree of heterogeneity was also seen for MSP-3~K1~ associations (*I* ^2^ = 76.8%, 95% CI 24.4--92.9) so results were not combined ([Figure 6](#pmed-1000218-g006){ref-type="fig"}). Due to the small number of studies in these meta-analyses, exploration of heterogeneity by subgroup analysis was not feasible.

Association between anti-AMA-1 Responses and Incidence of *P. falciparum* Malaria {#s3e}
---------------------------------------------------------------------------------

There are currently two different AMA-1 strains of the full-length ectodomain under development as vaccine candidates (FVO and 3D7) [@pmed.1000218-Richards1]. There was evidence of reduced risk of symptomatic *P. falciparum* with AMA-1~3D7~ responders versus nonresponders (RR 0.79, 95% CI 0.65--0.96, *p* = 0.015), and there was also a tendency towards a protective effect in the study that examined tertiles ([Figure 7](#pmed-1000218-g007){ref-type="fig"}) [@pmed.1000218-Gray1],[@pmed.1000218-Polley3],[@pmed.1000218-Stanisic1]. For AMA-1~FVO~, one study showed a reduced risk of symptomatic *P. falciparum* in AMA-1~FVO~ responders compared to nonresponders (RR 0.66 95% CI 0.52--0.84, *p* = 0.0007), but combined results of two studies showed no association of anti-AMA-1~FVO~ levels (log base 2) with incidence risk of symptomatic *P. falciparum* (RR 0.99, 95% CI 0.9--1.08, *p* = 0.76; [Figure 7](#pmed-1000218-g007){ref-type="fig"}) [@pmed.1000218-Nebie1],[@pmed.1000218-Dodoo3],[@pmed.1000218-Polley3]. There was insufficient evidence to show an association between AMA-1 responses with risk of reinfection and high density *P. falciparum* (see [Text S2](#pmed.1000218.s002){ref-type="supplementary-material"}).

![Forest plot of the association of AMA-1 responses with incidence of symptomatic *P. falciparum* malaria.\
RRs correspond to risk of symptomatic *P. falciparum* malaria for AMA1 responders versus nonresponders, High (H) and medium (M) versus low (L) responders (based on tertiles because sero-prevalence was high) and per doubling of antibody responses (log base 2). RR\<1 indicate that antibody responses are protective against symptomatic *P. falciparum* whereas RR\>1 indicate susceptibility. ^a^Estimates are calculated by authors from data in the paper; ^b^estimates are published estimates; ^c^estimates supplied by the original authors. All estimates are unadjusted with the exception of Dodoo (2008) and Nebie (2008) with adjustments for age and Stanisic (2009) with adjustments for age and spatial confounders [@pmed.1000218-Nebie1],[@pmed.1000218-Dodoo3],[@pmed.1000218-Stanisic1]. Polley (2004) stratified for two study sites in Coastal Kenya, \*Chonyi and \*\*Ngerenya.](pmed.1000218.g007){#pmed-1000218-g007}

Association between Anti-GLURP Responses and Incidence of *P. falciparum* Malaria {#s3f}
---------------------------------------------------------------------------------

GLURP can be divided into an N-terminal nonrepeat region (R0), a central repeat region (R1), and a C-terminal repeat region (R2). A reduced risk of symptomatic *P. falciparum* was shown in GLURP-R0 responders compared to nonresponders (RR 0.69, 95% CI 0.48--0.97, *p* = 0.032) and per doubling of antibody levels (RR 0.79, 95% CI 0.69--0.91, *p* = 0.0006; [Figure 8](#pmed-1000218-g008){ref-type="fig"}) [@pmed.1000218-Nebie1],[@pmed.1000218-Nebie2],[@pmed.1000218-Dodoo3]. Dodoo et al. (2000) also reported that anti-GLURP-R0 levels were associated with protection (*p*\<0.005), but no estimates or 95% CI were given [@pmed.1000218-Dodoo2]. Conversely, Lusingu et al. (2005) reported no association with anti-GLURP-R0 responders with odds (RR were incalculable) of symptomatic episode (OR 1.13, 95% CI 0.5--2.53, *p* = 0.77) [@pmed.1000218-Lusingu1].

![Forest plot of the association of GLURP responses with incidence of symptomatic *P. falciparum* malaria.\
RRs correspond to risk of symptomatic *P. falciparum* malaria for GLURP responders versus nonresponders and per doubling of antibody responses (log base 2). RR\<1 indicate that antibody responses are protective against symptomatic *P. falciparum* whereas RR\>1 indicate susceptibility. ^a^Estimates are published estimates with adjustments for age, Nebie (2008) responder versus nonresponder analysis also adjusted for sex and village [@pmed.1000218-Nebie2]; ^b^estimates are calculated by authors from data in the paper. GLURP-R2 estimates were not combined because *I* ^2^\>75%. W, weight.](pmed.1000218.g008){#pmed-1000218-g008}

GLURP-R2 was associated with protection to varying degrees. Meraldi et al. and Nebie et al. showed a 90% (RR 0.1, 95% CI 0.05--0.23, *p*\<0.001) and 27% (RR 0.73, 95% CI 0.5--1.06, *p* = 0.1; [Figure 8](#pmed-1000218-g008){ref-type="fig"}) reduction in symptomatic malaria in responders versus nonresponders [@pmed.1000218-Meraldi1],[@pmed.1000218-Nebie2]. Estimates from these two studies were not combined (*I* ^2^ = 94.5%). Another study found no evidence of an association between anti-GLURP-R2 (*p* = 0.2) or GLURP-R1 (*p* = 0.3) levels (estimates and 95% CI, DNS) [@pmed.1000218-Dodoo2]. One study examined the association of GLURP-R1-R2 with malaria, which showed a reduced risk of symptomatic *P. falciparum* (RR 0.73, 95% CI 0.55--0.97, *p* = 0.03) [@pmed.1000218-Dziegiel1].

Association between Other Responses and Incidence of *P. falciparum* Malaria {#s3g}
----------------------------------------------------------------------------

Only three studies meeting our inclusion and quality criteria measured anti-EBA-175 responses [@pmed.1000218-Okenu1],[@pmed.1000218-John2],[@pmed.1000218-Osier2]. Osier et al. (2008) (used recombinant F2 domain) and Okenu et al. (2000) (used recombinant region II) showed no association of anti-EBA-175 antibodies with risk of symptomatic *P. falciparum* (responders versus nonresponders, RR 1.36, 95% CI 0.81--2.3, *p* = 0.246 for Osier et al.; RR 0.96, 95% CI 0.71--1.29, p = 0.77 for Okenu et al.). John et al. (2005) showed no association between antibodies (to region II) and risk of reinfection (\>75 percentile versus \<75% percentile 1.25, 95% CI 0.66--2.36, *p* = 0.49). One study investigated the relationship between MSP-4 and MSP-4-EGF1 with risk of reinfection and showed no association (RR 0.9, 95% CI 0.58--1.39, *p* = 0.64 and RR 0.8, 95% CI 0.56--1.15, *p* = 0.22, respectively) [@pmed.1000218-Wang1].

Discussion {#s4}
==========

This systematic review strongly supports the protective effect of total IgG responses to particular merozoite surface antigens against symptomatic *P. falciparum* malaria in humans. Meta-analyses showed that individuals who have IgG to MSP-3-Ct and MSP-1~19~ have a risk of symptomatic *P. falciparum* that is 54% and 18%, respectively, less than those without detectable IgG. Moreover, there was evidence of a dose-response relationship such that the magnitude of association with these antigens increased per doubling of antibody levels. A tendency towards protective RR was also observed when individual estimates for AMA-1~3D7~ and GLURP-R0 were examined, but pooled estimates of more than two studies could not be determined owing to heterogeneity among studies. Pooled estimates showed limited evidence of a protective effect of IgG responses towards MSP-2, MSP-1 N-terminal region, or MSP-1-EGF subregion with symptomatic *P. falciparum* malaria. Importantly, this systematic review revealed a paucity of studies examining the association of IgG responses towards the vaccine candidates MSP-1~42~ and EBA-175 with incidence of *P. falciparum* malaria.

Heterogeneity, in terms of both clinical and methodological diversity between studies, was an important issue in the meta-analyses. Clinical heterogeneity was noted in MSP-1~19~ meta-analyses whereby the magnitude of effect varied with allelic group. However, given that MSP-1~19~ is relatively conserved and that the different alleles are based on four amino acid changes, the biological relevance of this observation is unknown. Methodological heterogeneity was most evident across studies investigating AMA-1 and GLURP responses. Antibody variables were defined differently across studies and estimates with errors and/or raw data were not presented. Subsequently the standardization of antibody variables and pooling of results was problematic. Statistical heterogeneity (*I* ^2^ value) was greatest for GLURP R2 and the full length MSP-3 antigen meta-analyses.

There are many factors influencing the selection of antigens for vaccine development and testing in clinical trials, and evidence from observational studies can provide valuable knowledge to inform this process. MSP-1~19~ was the most featured merozoite surface antigen and meta-analyses showed that antibody responses to MSP-1~19~ were indicative of protection. It is thus surprising that MSP-1~19~ has only featured in one vaccine in humans, in which it was used in combination with AMA-1 (PfCP2.9/ISA720) in phase I trials [@pmed.1000218-Hu1],[@pmed.1000218-Malkin1]. Conversely, only one study has demonstrated evidence of protection for antibodies to MSP-1~42~, but this antigen has been tested in a phase II vaccine trial where it was not protective [@pmed.1000218-Ogutu1]. The reasons for the failure of this vaccine remain unclear, but may relate to antigen polymorphism or the nature of the vaccine-induced response, or instead may indicate that MSP-1~42~ antibodies are not protective. Further studies of this antigen are clearly needed. Other merozoite surface antigens currently undergoing phase II trials in malaria endemic countries include AMA-1 (AMA-C1, which includes 3D7 and FVO strains) and MSP-3 (as a long synthetic peptide and a MSP-3/GLURP chimera), which were shown to be protective against symptomatic malaria in this review [@pmed.1000218-Richards1]. There are currently no vaccines with MSP-1-block 1 and 2 proteins, and data from this systematic review does not support the development of these antigens as vaccine targets.

The aim of this systematic review was to be as comprehensive and inclusive as possible and fulfil guidelines for meta-analyses [@pmed.1000218-Stroup1]. We performed an extensive search of six different databases and did not limit our searches by language to remove the potential for bias due to exclusion of non-English studies [@pmed.1000218-Moher1]. Furthermore, we identified and contacted the investigators for the studies that did not meet our initial inclusion and quality criteria but contained potential data. In addition, instead of excluding studies that did not provide estimates, we contacted authors and asked them to provide estimates or data. We did not limit our review to IgG subclasses as it would substantially decrease the number of studies included. Examining subclass-specific responses to merozoite antigens has provided further insights into protective targets and mechanisms of acquired immunity [@pmed.1000218-Stanisic1],[@pmed.1000218-Roussilhon1]. However, differences in the specificity and sensitivity of subclass-typing reagents between studies makes comparisons between studies difficult. We also assessed publication bias where possible, although in some cases where only a few studies were combined this assessment was difficult. The extent to which the selective publication of studies based on the direction and magnitude of findings within malaria epidemiological research is unknown. The publication of all studies regardless of findings should be encouraged.

Determining a causal relationship between antibodies and protection against *P. falciparum* malaria is one of the main challenges in malaria immuno-epidemiology. Study designs used in the published literature include cross-sectional studies, case-control studies, and cohort studies. To ensure the best inference of causality from the published literature we did two things. Firstly, we only included studies that examined the association of antibodies with prospectively collected *P. falciparum* data to establish a temporal relationship between antibody responses and risk of *P. falciparum* malaria. Secondly, we included a parasitaemia density cut-off in our definition of symptomatic malaria as part of our quality criteria to improve specificity and ensure that *P. falciparum* was the causative agent of the febrile episode. The prevailing view in the field is that a cut-off level of parasitaemia is needed to improve the specificity of clinical malaria diagnosis in most populations [@pmed.1000218-Mabunda1]--[@pmed.1000218-Smith1]. The population-specific definitions of a high *P. falciparum* density cut-off in the studies ranged from \>300 parasites/µl to \>5,000 parasites/µl and the sensitivity of these definitions would vary across populations. In addition, we would expect reduced specificity of the definition for the one study that reanalysed data with a high density cut-off for inclusion in our review [@pmed.1000218-Scopel1].

A causal relationship between anti-merozoite antibodies and *P. falciparum* malaria is strengthened by the consistent demonstration of findings under different circumstances. Consistent findings were demonstrated for some antigens despite differences in the preparation of antigens, malaria endemicity, study participants, and study area. Interestingly, we found very few published studies that were performed outside Africa. Of the 32 included studies, only one was performed in Asia (excluding Papua New Guinea) and only one in South America (see [Table 1](#pmed-1000218-t001){ref-type="table"}). The generalizability of our findings to populations living in these less-represented regions is unknown. Additionally, we only identified two studies that investigated allele-specific immunity (both studies MSP-2 only), whereby the allele-specific antibody response was related to the strain causing the malaria episode [@pmed.1000218-Stanisic1],[@pmed.1000218-Scopel1]. If protection is purely allele-specific then the true causal protective effect will be underestimated in studies that do not use allele-specific *P. falciparum* outcomes.

Another important limitation in published literature is that data generated by ELISA does not produce a common metric measurement thereby restricting the standardization of exposure variables. In meta-analyses we were able to pool RR for responders versus nonresponders and RR derived from log base 2 antibody levels, which represent the change in risk per doubling of antibody levels. However, antibody concentrations vary across populations according to the level of exposure to malaria. Therefore the magnitude of effect according to quantified responses may vary significantly across studies. This was evident by the dose-dependent relationships between some antibody responses and level of protection and would suggest that antibody responses need to be quantified. Furthermore, knowledge on how long specific merozoite antibody responses last, how they are boosted, and the duration of any protection from responses is presently limited. The duration of the follow up in observational studies may therefore have an impact on the strength and direction of an association, an effect we explored in meta-regression. Further studies that measure responses at multiple time points are needed to better understand these issues.

The definition of "protected" individuals (i.e., those who did not have symptomatic malaria) varied across studies. For most studies this definition included all participants who had no recorded episodes of symptomatic *P. falciparum* malaria. Three studies excluded individuals who did not have any detected parasitaemia during follow-up from the "protected" group, on the basis that these individuals were unexposed [@pmed.1000218-Dziegiel1]--[@pmed.1000218-Taylor1]. Only the six treatment-to-reinfection studies had regular blood collection for detection of parasitaemia; all other included studies only collected blood slides during follow-up when an individual was febrile, so accurately determining true "unexposed" individuals in areas where asymptomatic parasitaemia is prevalent will be problematic. Recent analyses by Bejon et al. (2009) of anti-VSA antibodies in individuals living in Kilifi, Kenya, showed that by removing unexposed children from conventional analyses, the magnitude of effect was greater between those with high and low responses [@pmed.1000218-Bejon1]. This is consistent with other studies in Kilifi that showed that associations between specific merozoite antibody responses and protection were stronger in children who were asymptomatic at baseline [@pmed.1000218-Polley3],[@pmed.1000218-Polley4],[@pmed.1000218-Osier2]. A further consideration is that studies in malaria-endemic areas typically compare individuals with different levels of immunity, not individuals with complete immunity versus individuals with no immunity. Therefore, the reported effect size may not accurately reflect the true magnitude of the response in the study population.

Conclusion and Guidelines for Future Research {#s4a}
---------------------------------------------

IgG responses to some, but not all, merozoite surface antigens were associated with protection against symptomatic *P. falciparum* in malaria endemic areas. We identified very few antigens that had been well studied and a deficiency of studies done outside Africa. More studies in different populations, examining multiple antigens at multiple time-points, are needed to better determine the role of anti-merozoite antibodies in protection against malaria, with prospective cohort studies as the preferred study design to establish temporal causality. In the future, there should be as much uniformity between studies as possible to ensure maximum comparability. This could be improved by the quantification and standardization of IgG responses, which could be achieved by establishing a reference reagent for determining antibody concentrations. Furthermore, the protective effects of anti-merozoite responses observed epidemiologically must also be supported by evidence of the function of the antibodies. Development and application of functional assays rather than standard immunoassays would also be highly valuable. Presently, data on the function of antibodies against merozoite antigens is very limited [@pmed.1000218-Hodder1],[@pmed.1000218-Oeuvray1],[@pmed.1000218-Persson1],[@pmed.1000218-Egan2]. Lastly, there is a need to incorporate strain-specific responses and endpoints to address whether protective responses against particular antigens are strain-transcending or strain-specific.

A challenging aspect of this systematic review was the standardization of exposure and outcome measurements as there is no consistent approach to reporting of data. To facilitate the standardization of results in future studies, we propose guidelines for the reporting of malaria immuno-epidemiology studies adapted from the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement ([Table 3](#pmed-1000218-t003){ref-type="table"}) [@pmed.1000218-Vandenbroucke1],[@pmed.1000218-vonElm1]. Standardizing studies, and removing as much methodological heterogeneity as possible, will help obtain more comparable results in the future. By doing so, we will then be in a more favourable position to assess the relative contribution of responses to certain antigens, thereby informing vaccine candidate choices.

10.1371/journal.pmed.1000218.t003

###### Proposed guidelines of the reporting of Malaria Immuno-epidemiology Observational Studies (MIOS guidelines).

![](pmed.1000218.t003){#pmed-1000218-t003-3}
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                                                **---**                                                                                                                                                                                                                                                            State objectives, including any prespecified hypotheses (i.e., protection, no effect).
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                                                **---**                                                                                                                                                                                       Study design, describe exactly how and when immune response, *Plasmodium* and clinical data collection took place. For longitudinal studies discriminate between serial cross-sectional studies and longitudinal cohort studies.
                                                **---**                                                                                                                                                                                                                                  Relevant dates such as participant recruitment, measurement of immune responses, follow-up, and *Plasmodium* and clinical data collection.
                                                **---**                                                                                                                                                                                                                                                     Eligibility criteria and sources and methods of selection of participants. Justification of criteria.
                                                                                                                                                                                                                                                        Methods of follow-up and data collection. Indicate intervals for ACD and the appropriateness of the use of PCD in the setting. Indicate how presumptive malaria diagnosis was dealt with in data collection.
                                                **---**                                                                                                                                                                                                                                                                      A description of any efforts to address potential sources of bias.
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                                                **---**                        The demographic and clinical characteristics of the participants and information on exposures and potential confounders. Indicate the number of participants with missing data for each variable of interest. Summarize follow-up times if applicable and mention changes in incidence of *Plasmodium* over follow-up. Consider presenting clinical and immunology data according to age group to give the reader a sense of the acquisition of immunity in the study population or by immunological response categories so they can be related to confounders.
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                                                **---**                                                                                                                                                                                                                                                          Details of any quantification of antibody or other concentrations (i.e., titres in µg/ml).
                                                **---**                                                                                                                                                                                                                       Counts of cases, controls, person-time at risk, risk etc. for each immune response category in addition to effect-measure estimates and results of model fitting.
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                                                **---**                                                                                                                           Separate estimates for each immune response. Also assess joint effects and interactions between immune responses. Consider both additive and multiplicative scales (i.e., does the combined effect of response *A* and *B* add (*a*+*b*)% or (*a*×*b*)% to risk?). This will help assess the relative contribution of each immune response to protection.
                                                **---**                                                                                                                                                                                                                                                                Separate estimates for different lengths of follow-up. E.g., 1, 3, 6, 9, 12 mo.
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                                                **---**                                                                                                                                               Give a balanced interpretation of the results considering limitations. Discuss both direction and magnitude of effects and pay particular attention to evidence of no effect versus no evidence of an effect. Outline possible methodological reasons for why the current results may differ from other studies.
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ACD

:   active case detection

AMA-1

:   apical membrane antigen-1

BL

:   block

CI

:   confidence interval

Ct

:   C terminus

DNS

:   data not shown in original manuscript

EBA

:   erythrocyte binding antigen

EGF

:   epidermal growth factor-like module

ELISA

:   enzyme-linked immunosorbent assay

GLURP

:   glutamate-rich protein

HR

:   hazard ratio

Ig

:   immunoglobulin

IRR

:   incidence rate ratio

ln

:   natural logarithm

MSP

:   merozoite surface protein

OR

:   odds ratio

PCD

:   passive case detection

reRR

:   pooled risk ratio using random-effects

RR

:   risk ratio

VSA

:   variant surface antigen
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